Estimated 84 patient nafamostat late treatment RCT with results not reported over 5 years after estimated completion.
Study covers TMPRSS2 inhibitors and nafamostat.
1.
Seydi et al., Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal, NCT04390594, clinicaltrials.gov/study/NCT04390594.
2.
Kim et al., A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19, NCT04871646, clinicaltrials.gov/study/NCT04871646.
Bae et al., 30 Apr 2021, Randomized Controlled Trial, South Korea, trial NCT04418128 (history).
Contact: ttezebae@gmail.com, lannya@naver.com.
Late treatment
is less effective
is less effective
bae3